These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


1375 related items for PubMed ID: 16766096

  • 1. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK, Botham L, Schoub BD.
    Vaccine; 2006 Jul 17; 24(29-30):5670-8. PubMed ID: 16766096
    [Abstract] [Full Text] [Related]

  • 2. Cost analysis of post-polio certification immunization policies.
    Sangrujee N, Cáceres VM, Cochi SL.
    Bull World Health Organ; 2004 Jan 17; 82(1):9-15. PubMed ID: 15106295
    [Abstract] [Full Text] [Related]

  • 3. Economics of polio vaccination in the post-eradication era: should OPV-using countries adopt IPV?
    Khan MM.
    Vaccine; 2008 Apr 07; 26(16):2034-40. PubMed ID: 18339460
    [Abstract] [Full Text] [Related]

  • 4. Polio immunization policy in Mexico: economic assessment of current practice and future alternatives.
    Mascareñas A, Salinas J, Tasset-Tisseau A, Mascareñas C, Khan MM.
    Public Health; 2005 Jun 07; 119(6):542-9. PubMed ID: 15826896
    [Abstract] [Full Text] [Related]

  • 5. Cost-effectiveness of incorporating inactivated poliovirus vaccine into the routine childhood immunization schedule.
    Miller MA, Sutter RW, Strebel PM, Hadler SC.
    JAMA; 1996 Sep 25; 276(12):967-71. PubMed ID: 8805731
    [Abstract] [Full Text] [Related]

  • 6. Budget impact of polio immunization strategy for India: introduction of one dose of inactivated poliomyelitis vaccine and reductions in supplemental polio immunization.
    Khan MM, Sharma S, Tripathi B, Alvarez FP.
    Public Health; 2017 Jan 25; 142():31-38. PubMed ID: 28057194
    [Abstract] [Full Text] [Related]

  • 7. The costs of future polio risk management policies.
    Tebbens RJ, Sangrujee N, Thompson KM.
    Risk Anal; 2006 Dec 25; 26(6):1507-31. PubMed ID: 17184394
    [Abstract] [Full Text] [Related]

  • 8. [Economic impact of introducing the injectable inactivated polio vaccine in Colombia].
    Alvis N, De la Hoz F, Narváez J.
    Rev Panam Salud Publica; 2010 May 25; 27(5):352-9. PubMed ID: 20602069
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia.
    Tucker AW, Isaacs D, Burgess M.
    Aust N Z J Public Health; 2001 Oct 25; 25(5):411-6. PubMed ID: 11688618
    [Abstract] [Full Text] [Related]

  • 10. World wide experience with inactivated poliovirus vaccine.
    Bonnet MC, Dutta A.
    Vaccine; 2008 Sep 15; 26(39):4978-83. PubMed ID: 18680777
    [Abstract] [Full Text] [Related]

  • 11. A developing country perspective on vaccine-associated paralytic poliomyelitis.
    John TJ.
    Bull World Health Organ; 2004 Jan 15; 82(1):53-7; discussion 57-8. PubMed ID: 15106301
    [Abstract] [Full Text] [Related]

  • 12. Polio eradication: the OPV paradox.
    Dowdle WR, De Gourville E, Kew OM, Pallansch MA, Wood DJ.
    Rev Med Virol; 2003 Jan 15; 13(5):277-91. PubMed ID: 12931339
    [Abstract] [Full Text] [Related]

  • 13. Introduction of inactivated polio vaccine (IPV) into the routine immunization schedule of South Africa.
    Schoub BD.
    Vaccine; 2012 Sep 07; 30 Suppl 3():C35-7. PubMed ID: 22939019
    [Abstract] [Full Text] [Related]

  • 14. Sequential inactivated (IPV) and live oral (OPV) poliovirus vaccines for preventing poliomyelitis.
    Ciapponi A, Bardach A, Rey Ares L, Glujovsky D, Cafferata ML, Cesaroni S, Bhatti A.
    Cochrane Database Syst Rev; 2019 Dec 05; 12(12):CD011260. PubMed ID: 31801180
    [Abstract] [Full Text] [Related]

  • 15. The role of routine polio immunization in the post-certification era.
    Sutter RW, Cáceres VM, Mas Lago P.
    Bull World Health Organ; 2004 Jan 05; 82(1):31-9. PubMed ID: 15106298
    [Abstract] [Full Text] [Related]

  • 16. Introduction of inactivated poliovirus vaccine leading into the polio eradication endgame strategic plan; Hangzhou, China, 2010-2014.
    Liu Y, Wang J, Liu S, Du J, Wang L, Gu W, Xu Y, Zuo S, Xu E, An Z.
    Vaccine; 2017 Mar 01; 35(9):1281-1286. PubMed ID: 28161421
    [Abstract] [Full Text] [Related]

  • 17. Poliovirus vaccine options.
    Zimmerman RK, Spann SJ.
    Am Fam Physician; 1999 Jan 01; 59(1):113-8, 125-6. PubMed ID: 9917578
    [Abstract] [Full Text] [Related]

  • 18. Strengths and weaknesses of current polio vaccines--a view from industry.
    André FE.
    Dev Biol (Basel); 2001 Jan 01; 105():61-6. PubMed ID: 11763338
    [Abstract] [Full Text] [Related]

  • 19. [The perspective of global eradication of poliomyelitis].
    Knolle H, Egli A, Candrian U.
    Gesundheitswesen; 2004 Jan 01; 66(1):1-6. PubMed ID: 14767784
    [Abstract] [Full Text] [Related]

  • 20. Poliovirus vaccines. Progress toward global poliomyelitis eradication and changing routine immunization recommendations in the United States.
    Sutter RW, Prevots DR, Cochi SL.
    Pediatr Clin North Am; 2000 Apr 01; 47(2):287-308. PubMed ID: 10761505
    [Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 69.